Pandemic influenza A/H1N1 2009 antibodies in the metropolitan area of Buenos Aires in Argentina.

Autor:	Labato MI; Hospital de Clínicas 'José de San Martín', Universidad de Buenos Aires, Arenales 2557, 1° A (CP 1425), Buenos Aires, Argentina., Contrini MM; Hospital de Niños 'Ricardo Gutiérrez', Buenos Aires, Argentina., Lazzarini D; Hospital de Niños 'Ricardo Gutiérrez', Buenos Aires, Argentina., Campos AM; Servicio de Virus Respiratorios, Instituto Nacional de Enfermedades Infecciosas -Administración Nacional de Laboratorios e Institutos de Salud 'Dr. Carlos Malbrán', Buenos Aires, Argentina., Gauna ML; Hospital de Clínicas 'José de San Martín', Universidad de Buenos Aires, Arenales 2557, 1° A (CP 1425), Buenos Aires, Argentina., Claros R; Hospital de Clínicas 'José de San Martín', Universidad de Buenos Aires, Arenales 2557, 1° A (CP 1425), Buenos Aires, Argentina., López EL; Hospital de Niños 'Ricardo Gutiérrez', Buenos Aires, Argentina., Savy VL; Servicio de Virus Respiratorios, Instituto Nacional de Enfermedades Infecciosas -Administración Nacional de Laboratorios e Institutos de Salud 'Dr. Carlos Malbrán', Buenos Aires, Argentina., Luna CM; Hospital de Clínicas 'José de San Martín', Universidad de Buenos Aires, Arenales 2557, 1° A (CP 1425), Buenos Aires, Argentina. Electronic address: dr.cm.luna@gmail.com.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2014 Feb; Vol. 19, pp. 20-5. Date of Electronic Publication: 2013 Nov 06.
DOI:	10.1016/j.ijid.2013.09.021
Abstrakt:	Objective: To estimate the infection prevalence in Buenos Aires during the outbreak of pandemic influenza A/H1N1 2009 virus (A(H1N1)pdm09). Methods: A(H1N1)pdm09-specific antibodies were measured by hemagglutination inhibition assay in human serum samples collected 6 months after the outbreak and before the introduction of the A(H1N1)pdm09 vaccine in Argentina. Baseline levels of cross-reactive antibodies to A(H1N1)pdm09 were determined by testing 162 serum samples collected before 2009. Results: The overall seroprevalence of A(H1N1)pdm09 in 150 children and 427 adults was 28.9% (95% confidence interval (CI) 25-33%), with a 58.0% prevalence in children <19 years of age and an 18.7% prevalence in adults ≥19 years of age (p<0.001). The prevalence was 43.5% in children <5 years old and 60.6% among children aged 5-18 years. The prevalence in adults declined with increasing age: 24.9% in 19-39-year-olds, 9.7% in 40-59-year-olds, and 8.1% in those ≥60 years old. The prevalence of specific A(H1N1)pdm09 antibodies was higher compared with the baseline in children (p=0.014), adolescents (p<0.001), and adults <40 years old (p=0.017). Seroprevalence in health care workers was not different from the rest of the population (13.6% vs. 19.3%, respectively; p=0.421). Conclusions: The prevalence of specific A(H1N1)pdm09 antibodies was high at 28.9%. The highest prevalence was observed in children, adolescents, and young adults. (Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu